GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02759588
• Other study ID #: GL-ONC1-015
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 2016
• Est. completion date: December 31, 2022

Study information

• Verified date: January 2023
• Source: Genelux Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if GL-ONC1 oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.

Description:

Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, GL-ONC1, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 30 different human tumors, including ovarian cancer. GL-ONC1 has been investigated in early stage clinical trials in the United States and Europe via systemic delivery as monotherapy and in combination with other therapies, and via regional delivery as monotherapy. GL-ONC1 treatment was well tolerated across different malignancies, routes of administration, and monotherapy as well as combination therapy protocols. The ability of GL-ONC1 to infect tumor tissue and kill tumor cells was demonstrated. In addition, virus-induced immune activation and favorable anti-tumor immune response have been observed. Evidences of anti-tumor efficacy and clinical benefits have also been documented.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Signed, written informed consent.

• High-grade serous (including Malignant Mixed Mullerian Tumor (MMMT) with metastasis that contains high grade epithelial carcinoma), endometrioid, or clear-cell ovarian cancer which includes: (1) platinum-resistant (recurrence or progression in < 6 months) or (2) platinum-refractory (progression while on platinum-based therapy); patient must have failed either at least 2 consecutive therapies or are not eligible for additional cytotoxic therapies (exception is Phase 2 receiving chemotherapy with/without bevacizumab).

• Intermediate platinum-sensitive patients (recurrence of disease 6 to 12 months from last platinum compound treatment): Recurrent ovarian carcinoma with at least four prior individual treatment regimens including at least two separate platinum-based therapies with recurrence from the last platinum-based regimen less than 12 months, who are unwilling or unable to undergo additional platinum-based cytotoxic therapy (this sub-population is not applicable for Phase 2 receiving chemotherapy with/without bevacizumab).

• Performance status ECOG is at 0 or 1, and life expectancy of 6 months

• Has either measurable disease in the peritoneal cavity as defined by RECIST 1.1 (Phase 1b & 2) or has non-measurable disease in the peritoneal cavity (Phase 1b) and can be confirmed by laparoscopy and/or elevated CA-125. Patients who have non-measurable disease that is not identifiable by PET/PET-CT scan, but who have elevated CA-125, and/or ascites, with visible disease confirmed by laparoscopy are also eligible.

• Able to undergo IP injection.

• Adequate renal, hepatic, bone marrow and immune functions.

• Baseline tumor biopsy is required.

• Documented progressive disease status at baseline (Phase 2).

Exclusion Criteria:

• Tumors of mucinous subtypes, or non-epithelial ovarian cancers (e.g., Brenner tumors, Sex-cord tumors).

• Unresolved bowel obstruction.

• Known central nervous system (CNS) metastasis.

• Known seropositivity for HIV or active hepatitis infection.

• History of thromboembolic event within the last 3 months.

• Pregnant or breast-feeding women.

• Smallpox vaccination within 1 year of study treatment.

• Clinically significant cardiac disease.

• Received prior gene therapy or therapy with cytolytic virus of any type.

• Receiving concurrent antiviral agent active against vaccinia virus.

• Have known allergy to ovalbumin or other egg products.

• Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or unhealed skin wounds or ulcers) as assessed by the Investigator.

• Symptomatic malignant ascites and non-manageable pleural effusion.

• Known hypersensitivity to bevacizumab, uncontrolled hypertension, history of stroke, or clinical findings suggestive of excessive risk for GL perforation (uncontrolled peptic ulcer disease, partial small bowel obstruction, etc.) that would make risks of bevacizumab unacceptable in the opinion of the investigator.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Ovarian Neoplasms
• Peritoneal Carcinomatosis
• Peritoneal Neoplasms

Intervention

Biological:
• GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.

Locations

Country	Name	City	State
United States	Gynecologic Oncology Associates	Newport Beach	California
United States	AdventHealth Cancer Institute	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Genelux Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-emergent Adverse Events [Safety and Tolerability] (Phase 1b)	Determine safety and tolerability of administering multiple doses of GL-ONC1 via intraperitoneal catheter by the evaluation of the number of participants with treatment-emergent adverse events (type, frequency, and severity) as assessed by CTCAE 4.03.	Change from baseline during Treatment and for 30 days following last dose.
Primary	Determine Progression-free Survival following Treatment (Phase 2)	To assess progression-free survival (PFS) from time of registration until disease	From date of registration until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Primary	Tumor Marker Cancer Antigen-125 (CA-125) (Phase 2)	To assess anti-tumor response.	Assessed pre-treatment, during treatment at 2- to 3-week intervals and post-treatment assessed up to 24 months.
Primary	Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)	To assess anti-tumor response.	Assessed pre-treatment, during treatment at 6- to 12-week intervals and post-treatment assessed up to 24 months.
Secondary	Evaluation of Tumor Response to Treatment (Phase 1b)	Evaluate participant's best overall response to treatment with therapeutic intent assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. (i.e., complete response, partial response, stable disease, or progressive disease).	Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.
Secondary	Evaluation of Immune-related Tumor Response	Evaluate participants' best overall response to treatment with oncolytic immunotherapy assessed by Immune-related Response Criteria (immune-related complete response, immune-related partial response, immune-related stable disease, or immune-related progressive disease).	Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.
Secondary	CA-125 Response (Phase 1b)	CA-125 according to the Gynecologic Cancer Intergroup (GCIG) is measured by at least a 50% reduction in CA-125 levels from pre-treatment sample which is confirmed and maintained for at least 28 days. Pre-treatment CA-125 sample must be at least twice the upper limit of normal and obtained within 2 weeks prior to starting treatment.	Assessed pre-treatment, during treatment and post-treatment at 6 to 12 week intervals, assessed up to 24 months.
Secondary	Determine Progression-free Survival following Treatment (Phase 1b)	To assess progression-free survival (PFS) in participant population.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Secondary	Overall Survival	To determine overall survival (OS) in the participant population.	By medical chart review until death or 3 years from the date of last treatment which ever comes first.
Secondary	Clinical Benefit Rate	Defined as the percentage of patients who have achieved CR + PR + SD greater than or equal to 15 weeks.	Approximately 24 months

External Links

•   Sponsor's company website